Rachel Harland

Dr Rachel Harland joined ReViral in 2016 from Astra-Zeneca where she had been directing a wide range of toxicology programmes. Prior to her role at AZ Rachel was Director of Toxicology for Shire Pharmaceuticals. Rachel was Development Manager at two Biotechnology companies – Arrow Therapeutics Ltd (sold to Astra-Zeneca) and Q-Chip Ltd (now Midatech and listed on the LSE) where her development strategies were a key part of the company value. Rachel spent some 10 years at Roche Products initially as a Pre-clinical Science Leader and then as a Project Manager. Rachel gained both her BSc and PhD from the University of Liverpool.